Skip to main content
SpringerLink
Log in

Dermatotherapie in der Schwangerschaft

Dermatologic therapy in pregnancy

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Pharmakotherapie der schwangeren Patientin bedarf einer besonderen Sorgfalt bei der Auswahl der verwendeten Wirksubstanzen, deren Dosierung und Administration. Dabei müssen das teratogene Risiko und der therapeutische Nutzen für die Mutter und möglicherweise auch für die Frucht abgewogen und die besondere Sorgfalts- und Dokumentationspflicht der Off-label-Anwendung beachtet werden. Der Beitrag befasst sich mit allgemeinen Aspekten der Nutzen-Risiko-Abwägung, nimmt zur teratogenen Potenz dermatologisch relevanter Arzneistoffe Stellung, formuliert Empfehlungen für häufige allgemeindermatologische Indikationen und zeigt weiterführende Informationsmöglichkeiten für spezielle Fallkonstellationen auf.

Abstract

Pharmacologic therapy of a pregnant patient requires particular care in selecting the active substances to be used, their dosage and administration. The teratogenic risk and the therapeutic benefit must be carefully weighed for the mother and possibly also for the child, and attention paid to the special precautions and documentation obligations of off-label applications. This article addresses the general aspects of benefit-risk evaluation, provides an opinion on the teratogenic potency of dermatologically relevant medications, formulates recommendations for frequent general dermatological indications and lists additional possible information sources for special case constellations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bar J, Stahl B, Hod M et al (2003) Is immunosuppression therapy in renal allograft recipients teratogenic? A single-center experience. Am J Med Genet A 116:31–36

    Article  Google Scholar 

  2. Carter JD, Ladhani A, Ricca LR et al (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36:635–641

    Article  PubMed  Google Scholar 

  3. Chi C-C, Wang S-H, Kirtschig G et al (2009) Systematic review of the safety of topical corticosteroids in pregnancy. J Am Acad Dermatol 62:694–705

    Article  Google Scholar 

  4. Costedoat-Chalumeau N, Amoura Z, Duhaut P et al (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Arthritis Rheum 48:3207–3211

    Article  CAS  PubMed  Google Scholar 

  5. Einarson A, Bailey B, Jung G et al (1997) Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 78:183–186

    Article  CAS  PubMed  Google Scholar 

  6. Friese K, Mörike K, Neumann G, Windorfer A (2006) Arzneimittel in der Schwangerschaft und Stillzeit, 6. Aufl. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart

  7. Haas A, Maschmeyer G (2008) Antibiotikatherapie in der Schwangerschaft. Dtsch Med Wochenschr 133:511–515

    Article  CAS  PubMed  Google Scholar 

  8. Hale EK, Pomeranz MK (2002) Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol 41:197–203

    Article  PubMed  Google Scholar 

  9. Heikkila A, Erkkola R (1994) Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. Clin Pharmacokinet 27:49–62

    Article  CAS  PubMed  Google Scholar 

  10. Loureiro KD, Kao KK, Jones KL et al (2005) Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 136:117–121

    PubMed  Google Scholar 

  11. Martin PL, Oneda S, Treacy G (2007) Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol 58:138–149

    Article  CAS  PubMed  Google Scholar 

  12. Martin PL, Sachs C, Imai N et al (2010) Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol 89:351–363

    Article  CAS  PubMed  Google Scholar 

  13. Muallem MM, Rubeiz NG (2006) Physiological and biological skin changes in pregnancy. Clin Dermatol 24:80–83

    Article  PubMed  Google Scholar 

  14. Nast A, Bayerl C, Borelli C et al (2010) S2k-Leitlinie zur Therapie der Akne. J Dtsch Derm Ges 8(Suppl 2):S1–S59

    Article  Google Scholar 

  15. Polifka JE, Friedman JM (2002) Teratogen update: Azathioprine and 6-mercaptopurine. Teratology 65:240–261

    Article  CAS  PubMed  Google Scholar 

  16. Sannerstedt R, Lundborg P, Danielsson BR et al (1996) Drugs during pregnancy: an issue of classification and information to prescribers. Drug Saf 14:69–77

    Article  CAS  PubMed  Google Scholar 

  17. Schaefer C (2007) Off-label-use von Medikamenten in der Schwangerschaft. Frauenarzt 48:20–25

    Google Scholar 

  18. Schaefer C, Spielmann H, Vetter K (2006) Arzneimittelverordnung in Schwangerschaft und Stillzeit. Urban & Fischer, München Jena

  19. Schaefer C, Weber-Schöndorfer C (2005) Medikamentöse Therapie in der Schwangerschaft. Dtsch Arztebl 102:A2480–A2488

    Google Scholar 

  20. Stern RS, Lange R (1991) Outcomes of pregnancies among women and partners of men awith a history of exposure to methoxsalen photochemotherapy (PUVA) fort he treatment of psoriasis. Arch Dermatol 127:347–350

    Article  CAS  PubMed  Google Scholar 

  21. Stille W (2006) Antibiotikatherapie, Klinik und Praxis der antiinfektiösen Behandlung, 11. Aufl. Schattauer, Stuttgart New York

  22. Vaux KK, Kahole NCO, Jones KL (2003) Cyclophosphamide, methotrexate and cytarabine embryopathy: Is apoptosis the common pathway? Birth Defects Res A 67:403–408

    Article  CAS  Google Scholar 

  23. Von Mandach U (2003) Schwangere und stillende Frauen. In: Jaehde U, Radziwill R, Mühlebach S, Schunack W (Hrsg) Lehrbuch der Klinischen Pharmazie. Wissenschaftliche Verlagsgesellschaft mgH, Stuttgart, S 337–345

  24. Weisshaar E, Witteler R, Diepgen TL et al (2005) Pruritus in der Schwangerschaft. Gynakologe 38:153–166

    Article  Google Scholar 

  25. Young G, Jewell D (2001) Topical treatment for vaginal candidiasis (thrush) in pregnancy (review). Cochrane Database Syst Rev 4:CD000225

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Der Autor ist bzw. war als Prüfarzt, Referent, Kooperationspartner bzw. Berater für folgende pharmazeutische Unternehmen tätig: Abbott, Almirall, Astellas, Bayer, Bombastus, Dermapharm, Essex, Glaxo-Smith-Kline, Intendis, Jansen-Cilag, Leo, Mavena, Mibe, Novartis, Shire, Spirig, Stiefel, Pfizer, Reddys, Riemser, Sanofi-Aventis, Wolff.

Author information

Authors and Affiliations

  1. Universitätsklinik und Poliklinik für Dermatologie und Venerologie, Martin Luther Universität Halle-Wittenberg, Ernst-Kromayer-Str. 5, 06097, Halle, Deutschland

    J. Wohlrab

Authors
  1. J. Wohlrab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Wohlrab.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wohlrab, J. Dermatotherapie in der Schwangerschaft. Hautarzt 61, 1046–1051 (2010). https://doi.org/10.1007/s00105-010-2006-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-010-2006-8

Schlüsselwörter

Keywords

Search

Navigation